A study published in the American Journal of Preventive Medicine Focus indicates that over 8 million Americans, approximately 2.8% of the population, reported psilocybin use in the past year, according to the 2024 National Survey on Drug Use and Health. The survey, which included 58,000 respondents aged 12 and older, found that psilocybin users are predominantly white, male, younger, and more affluent than nonusers. Interest in psilocybin has surged due to its potential therapeutic uses for conditions such as depression and anxiety, particularly as regulatory restrictions have begun to ease. However, psilocybin remains classified as a Schedule I controlled substance federally. The study also highlights the risks associated with psilocybin use, especially when combined with other substances, and the lack of data on dosage and source potency due to self-reporting limitations. Researchers emphasize the need for public health awareness as psilocybin use becomes more common outside clinical settings, particularly among individuals with higher incomes who can afford therapy costs. The findings suggest that clinicians and policymakers should pay attention to this growing trend to develop effective harm reduction strategies.